Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia John Theurer Cancer Center, Hackensack, New Jersey